Business
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a
About this update from Corvus Pharmaceuticals, Inc.
[{"type":"text","content":"Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT\nBURLINGAME, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today provided a business update and announced financial results for the first quarter ended March 31, 2020.\n “In the first quarter, we continued enrolling patients across our three clinical stage programs and reported positive data updates for ciforadenant, the Adenosine Gene Signature, and CPI-818,” said Richard A. Miller, M.D., president and chief executive officer of Corvus. “With ciforadenant, CPI-006 and the Adenosine Gene Signature, we have a leadership position in the development of targeted medicines addressing the adenosine pathway. We look forward to providing another important update for ciforadenant at ASCO, where we will present new data in renal cell cancer, including data confirming the utility of the Adenosine Gene Signature as a predictive biomarker to identify patients most likely to respond to treatment with ciforadenant.” “We also worked closely with our clinical trial sites to quickly adapt and update our study protocols to ensure patient and healthcare provider safety in light of the COVID-19 pandemic. We are pleased that this enabled enrollment and follow-up activities for patients in our studies to continue with minimal disruption. Fortunately, we have had strong enrollment in our clinical studies up to this point, allowing us to collect important clinical data as the studies mature.” Recent Achievements Ciforadenant (CPI-444): A2A Receptor Antagonist of Adenosine Enrolled 25 patients with advanced refractory renal cell cancer (RCC) in an amended phase 1b/2 clinical trial evaluating ciforadenant in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody, intended to confirm earlier results published in Cancer Discovery describing the Adenosine Gene Signature, which is designed to identify patients most likely to respond to treatment with ciforadenant. In the Cancer Discovery study, for patients with available tumor biopsies, Adenosine Gene Signature positive patients had a 17% overall response rate by RECIST criteria vs 0% in Aden...